Aspire BioPharma, Inc. (ASBP) — Financial Flexibility Index
Latest as of March 2026:
-0.94x
Aspire BioPharma, Inc. (ASBP) has a Financial Flexibility Index of -0.94x as of March 2026. Free cash flow of $-3.04 Million (operating CF $-3.04 Million minus capex $0.00) represents -1% of total liabilities ($3.25 Million).
Financial Flexibility Index
-0.94x
Free Cash Flow / Total Liabilities
Free Cash Flow
$-3.04 Million
Operating CF − Capex
Total Liabilities
$3.25 Million
USD
Capital Expenditures
$0.00
USD
Aspire BioPharma, Inc. Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for Aspire BioPharma, Inc. across 5 annual periods. See ASBP working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Aspire BioPharma, Inc. (2021–2025)
Year-by-year free cash flow to debt coverage for Aspire BioPharma, Inc.. For the full company profile including market capitalisation, see how much is Aspire BioPharma, Inc. worth.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.64x | $-4.92 Million | $-4.92 Million | $7.69 Million | ▼ -307.6% |
| 2024 | -0.16x | $-265.19K | $-265.19K | $1.69 Million | ▲ +90.3% |
| 2023 | -1.62x | $-653.10K | $-653.11K | $403.33K | ▼ -1177.7% |
| 2022 | -0.13x | $-1.41 Million | $-1.41 Million | $11.12 Million | ▼ -14216.2% |
| 2021 | 0.00x | $-260.00 | $-260.00 | $293.70K | — |
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities